DIANE SEIMETZ1, JÖRG SCHNEIDER2
1.Principal Consultant
2. Associate Principal Consultant, Biopharma Excellence, Germany

Abstract

The biopharma sector is seeing a proliferation of mergers, partnerships and acquisitions, but deals can sometimes fail due to poor scientific due diligence. Diane Seimetz and Jörg Schneider at Biopharma Excellence outline a plan of action to help you get the most from your business relationships.

Companies or individuals planning to go into business with others need to take a lot of care, especially when scientific, technical and regulatory information about complex therapeutic products is involved. For biotech companies and academic developers wishing to partner with larger firms, the process of assessing potential partners or licensing agreements is perhaps best regarded as a form of scientific due diligence. If done correctly, it will ensure that all parties are happy with the agreement. Whether your biotech company is looking at licensing products or technology platforms, or at an M&A or partnering agreement, you need to be able to show your value to potential partners and equity providers.

EXPERIENCE AND RESOURCES
The main raison d’être of academic researchers is to create scientific knowledge from their research and to publish. But translating this knowledge to commercial biopharmaceutical products in a highly regulated environment requires additional skills.

For growing biotech companies and academic developers, the experience and resources of larger pharmaceutical companies are invaluabl ...